X

Phaarmasia Ltd Stock Analysis

Small Cap
Evaluated by 81 users | BSE: 523620 | NSE: |
Pharmaceuticals & Drugs
The company was incorporated on  February 6,1981 as Phaarmasia Private Limited, and the company was converted into a public limited company, Phaarmasia Limited on February 15, 1992, it is into manufacturing of pharmaceutical formulations. Company's facilities are spread over in...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 1.17%5.42%2.5%4.92%0.28%0.39%1.43%5.03%5.94%4.27%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 47.535.913.521.218.721.614.420.224.224.5
Y-o-Y Gr. Rt.--24.4%-62.3%56.6%-11.6%15.3%-33.6%40.5%19.9%1%
Adjusted EPS (Rs.) 0.140.330.260.520.010.060.240.841.060.79
Y-o-Y Gr. Rt.-135.7%-21.2%100%-98.1%500%300%250%26.2%-25.5%
Book Value per Share (Rs.) 11.9511.4611.0110.9111.1111.1810.8611.412.5613.43
Adjusted Net Profit 0.10.20.20.4000.20.60.70.5
Net Op. Cash Flow (Rs. Cr.) 2.1-2.10.10.20.50.3-0.10.90.10.1
Debt to Cash Flow from Ops 0.010000.040.07-0.820.253.341.06
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Phaarmasia Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales -7.1%5.5%19.4%1%
Adjusted EPS 21.2%139.6%48.8%-25.5%
Book Value per Share 1.33.97.36.9
Share Price -17.8% 2.5% -8% 121.1%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 1.112.82.34.710.050.331.384.845.834.12
Operating Profit Margin (%) 1.392.894.823.955.111.010.922.4433.35
Net Profit Margin (%) 0.20.621.31.660.030.191.132.842.992.21
Debt to Equity 0000000.010.030.020.01
Working Capital Days 68132333140606388113191293
Cash Conversion Cycle -39-45-360-57-20-44-53-39-47-17
Entity Percentage Holding
Promoters 73.45%
Institutions 0.06%
Non-Institutions 26.49%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Phaarmasia Ltd's performance infers:

Phaarmasia Ltd earnings have grown by 139.6%, whereas share price has appreciated 2.5% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Phaarmasia Ltd share prices over the last 10 years. Here is what we found out:

Phaarmasia Ltd share price has appreciated -17.8% annually over the past ten years.

The company was incorporated on  February 6,1981 as Phaarmasia Private Limited, and the company was converted into a public limited company, Phaarmasia Limited on February 15, 1992, it is into manufacturing of pharmaceutical formulations. Company's facilities are spread over in 3 acres of land with built up area of 90,000 sq.ft.

The company was established for  carrying on the business as manufacturers, buyers, sellers, importers, exporters, distributors, agents

The company was incorporated on  February 6,1981 as Phaarmasia Private Limited, and the company was converted into a public limited company, Phaarmasia Limited on February 15, 1992, it is into manufacturing of pharmaceutical formulations. Company's facilities are spread over in 3 acres of land with built up area of 90,000 sq.ft.

The company was established for  carrying on the business as manufacturers, buyers, sellers, importers, exporters, distributors, agents and or otherwise deal as wholesalers, or retailers in drugs, medicines, pharmaceuticals, chemicals and other intermediates, dyes pigments, paints, rubber chemicals, phyto chemicals, hormones, agro-chemicals, veterinary and poultry products, food and nutritional products, house-hold remedies, biological and herbal products.

Phaarmasia’s registered office is located at 16,Phase III, I.D.A Jeedimetla, Hyderabad, Andhra Pradesh 500 055, India.

The company had restructured its Paid up Share Capital account of 91,34,800 Equity Shares of Rs 10 each fully paid up as on 31st, March,2005 by reducing / debiting the amount of Rs 730.78 lakhs for setting off the Accumulated Losses of the Company and has further allotted 50,00,000 Equity Shares of Rs 10each to promoters and Associates for Rs 250 lakhs and balance to Unsecured Creditors as approved in the above Scheme of Arrangement.

Product range of the company includes:

Phaarmasia’s product range includes amexine, angicare, flamfort, nasorel, flemkof, ginadox, medix and ziron. Its amexine is an antibiotic, which is used for upper respiratory tract infections, mucolytic and expectorant.

Company also provides nasorel PR, which is a therapeutic category that comes under antihistamine and sympathomimetic.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback